Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridion in children 0-2 years old
NCT03728543Phase 3Unknown
- Sponsor
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. Primary endpoint: Recovery time of neuromuscular conduction at 2 minutes. Status: unknown.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03728543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03728543.